uploads/2018/02/Chart-07-3-1.jpg

Sanofi Pasteur’s 4Q17 Performance

By

Updated

Sanofi Pasteur

Sanofi’s (SNY) Human Vaccines segment operates under the brand name Sanofi Pasteur. Sanofi Pasteur includes vaccines for meningitis, dengue, influenza, polio, and pertussis. This segment also covers travel, adult, booster, and other endemic vaccines. 

Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17, reflecting 8.7% growth in operating revenues compared to 4Q17. This growth was driven by the strong increase in European sales, following the end of the joint venture between Sanofi Pasteur and Merck & Co. (MRK) in 2016. The chart below compares the revenues for Sanofi Pasteur since 1Q16.

Article continues below advertisement

Meningitis and pneumonia vaccines

Meningitis and pneumonia vaccines reported revenues of 81.0 million euros in 4Q17, a 27.1% decline in operating revenues compared to 4Q16. This decline was driven by lower sales in the US and European markets. This decline was partially offset by strong sales from emerging markets and nearly flat revenues from the rest of the world.

Adult and booster vaccines

Adult and booster vaccines reported revenues of 137.0 million euros in 4Q17, representing ~13.2% growth in operating revenues compared to 4Q16. This growth was driven by strong sales in Europe and the rest of the world markets. This portfolio’s growth was substantially offset by lower sales in the US markets and emerging markets.

Article continues below advertisement

Influenza vaccines

Influenza vaccines reported revenues of 502.0 million euros in 4Q17 for 28.4% growth in operating revenues compared to 4Q16. This growth was driven by strong sales in all markets.

Polio/Hib/pertussis vaccines

The Polio/Hib/pertussis vaccines reported revenues of 493.0 million euros in 4Q17, a 3.9% decline in operating revenues compared to 4Q16. This decline was driven by lower sales from the US, the rest of the world, and emerging markets, and it was partially offset by strong sales in the European markets.

Travel and other endemic vaccines

Sanofi’s (SNY) travel and other endemic vaccines reported revenues of 160.0 million euros in 4Q17, representing 55.1% growth in operating revenues compared to 4Q16. This growth was driven by strong sales in the US, Europe, and emerging market sales. This growth was partially offset by lower sales from the rest of the world.

The VanEck Vectors Pharmaceutical ETF (PPH) holds 4.3% of its total investments in Sanofi ADR (SNY), 4.4% in Johnson & Johnson (JNJ), 4.7% in Mylan NV (MYL), and 4.8% in Pfizer (PFE).

Advertisement

More From Market Realist